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There are conflicting data regarding the effects of
transplantation of bone marrow-derived cells (BM-
DCs) on the severity of diabetes. We therefore inquired
whether the competence of BMDCs is preserved on
adoptive transfer into diabetic (db/db) mice and how
the adoptive transfer of BMDCs affects vascular and
metabolic abnormalities in these mice. Recipient db/db
mice received infusions of BMDCs prepared from either
db/db or non-diabetic heterozygout mice (db/m) mice
and effects on endothelium-dependent relaxation, insu-
lin sensitivity, and renal function were evaluated. Re-
cipients of BMDCs from db/m, but not db/db donors
showed better glucose control, exhibited striking im-
provement in endothelium-dependent relaxation in re-
sponse to acetylcholine, and had partially restored re-
nal function. Improved glucose control was due to
enhanced insulin sensitivity, most likely secondary to
improved vascular function. Enhanced apoptosis of en-
dothelial progenitor cells under oxidative stress, as well
as decreased endothelial progenitor cell numbers were
responsible for the apparent functional incompetence
of BMDCs from db/db donors. Treatment of db/dbmice
with Ebselen restored the resistance of both BMDCs
and endothelial progenitor cells to oxidative stress ,
improved acetylcholine-induced vasorelaxation,
and reduced proteinuria in db/db recipients of BMDC
transplantation. In conclusion, infusion of BMDCs
obtained from db/m donors to db/db recipient mice
benefited macrovascular function, insulin sensitivity,
and nephropathy. BMDCs obtained from db/db mice
were functionally incompetent secondary to the in-
creased proportion of apoptotic cells on oxidative
stress challenge; their competence was restored by
Ebselen therapy. (Am J Pathol 2009, 174:701–711; DOI:
10.2353/ajpath.2009.080606)
Transplantation of bone marrow-derived cells (BMDCs)
has emerged as a promising tool in regenerative medi-
cine. This heterogeneous cell population, consisting of
hematopoietic stem cells (HSCs), mesenchymal stem
cells (MSCs), and endothelial progenitors, has the ca-
pacity to differentiate into cells of endothelial, epithelial,
cardiomyocyte, and neuronal lineage.1–4 In a model of
hindlimb ischemia, implantation of autologous BMDCs
resulted in therapeutic angiogenesis and improved vas-
cularization of the affected limb in both non-diabetic and
diabetic rats.5 In ApoE-deficient mice, transplantation of
BMDCs resulted in the restoration of vascular functions.6
There are conflicting data on the effect of transplantation
of BMDCs on the severity of diabetes7–10 and on the renal
pathology and dysfunction in the murine model of renal
fibrosis and ischemia-reperfusion injury.11,12 Further-
more, recent data indicate that BMDC may become in-
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competent with regard to their ability to regenerate vari-
ous tissues and organs.6,13 Taking into account multiple
macro- and microvascular complications of diabetes, we
inquired a) whether transplantation of BMDCs may affect
some of these functional abnormalities, and b) whether
the competence of BMDCs in diabetic mice is preserved.
Here, we report a dramatic improvement of macrovascu-
lar dysfunction and insulin sensitivity in db/dbmice recip-
ients of syngeneic BMDC isolated from the non-diabetic
mice (but not from their diabetic counterparts), and provide
evidence for BMDC incompetence in diabetic animals.
Materials and Methods
Animals, Experimental Design, and Bone
Marrow Adoptive Transfer
The animal study protocol was in accordance with Na-
tional Institutes of Health (NIH) Guide for the Care and Use
of Laboratory Animals (U.S. Department of Health and
Human Services Public Health Services, NIH, NIH Publi-
cation No. 86–23, 1985) and approved by the Institutional
Animal Care and Use Committee. The type II diabetic
murine model db/db mice and db/m mice were obtained
from Jackson Laboratory (Bar Harbor, Maine; C57BL/6
background). The body weight and blood glucose level
of mice between ages of 8 to 16 weeks were monitored
throughout the study. Briefly, bone marrow from male
donor db/db and db/m mice was flushed under sterile
conditions with Hank’s balanced salt solution (HBSS)
from the medullary cavities of tibiae and femurs using a
21-gauge needle. Whole bone marrow single cell sus-
pension was fractionated using Histopaque-1077 solu-
tion (Sigma) gradient separation. Mononuclear cells were
collected, washed, and checked for viability using trypan
blue exclusion technique.8 BMDCs were labeled with Cell
Tracker (CM-DiI) (Invitrogen, Eugene, OR). In three inde-
pendent experiments, male recipient db/db mice (age 16
weeks) received approximately 106 BMDC by tail vein
injection. The db/db mice that received the BMDC from
db/m mice are designated as dbTxm. The db/db mice
that received the BMDC from db/db mice are designated
as dbTxdb. The same transfusion procedure was re-
peated three times every 10 days. In additional series of
experiments, db/db mice were treated with Ebselen by
gavage, twice a day at 5 mg/kg/day, dissolved in 5%
carboxymethyl (CM) cellulose suspension. This group of
donor mice was labeled as dbEbs-in vivo and its corre-
sponding recipient db/db mice were designated as Txd-
bEbs-in vivo. Control db/db mice received only CM cellu-
lose (Sigma, St. Louis, MO) suspension (vehicle treatment;
designated as dbCM and its corresponding BMDC recipi-
ent db/db mice designated as TxdbCM.) Another group of
recipient db/db mice was transfused with BMDC of db/db
origin, but treated with Ebs (1 g/ml) overnight in full Dul-
becco’s Modified Eagle Medium (DMEM) medium at 37°C
in CO2 incubator before transfusion. This group of recipient
mice was designated as TxdbEbs-ex vivo. Because all an-
imals had the same C57BL/6 background, no alloimmune
or graft-versus-host response was expected (nor ob-
served). Mice were euthanized 20 days after the final trans-
fusion (at age 23 weeks) by intraperitoneal injection of ket-
amine/xylazine (60/7.7 mg/kg, respectively). A mid-
laparotomy was performed and blood, thoracic aorta,
kidney, and pancreas were harvested for further analyses.
Acetylcholine-Induced Vasorelaxation
Thoracic aortas were cleared of periadventitial tissue and
cut transversely into rings 1.5 to 2.0 mm in diameter. Vas-
cular rings, handled carefully to avoid damage to the inner
surface, were mounted on wires in the chambers of a mul-
tivessel myograph (J.P. Trading, Aarhus, Denmark) and
bathed in Krebs’ buffer. The medium was gassed with 95%
O2 and 5% CO2 and maintained at 37°C (pH 7.4). After
equilibration (30 minutes), the rings were set to an internal
circumference equivalent to 90% of full relaxation under a
transmural pressure of 100 mm Hg and allowed to stabilize
for 20 to 30 minutes. The rings were then depolarized with
potassium chloride (60 mmol/L) to evaluate maximal con-
traction. After washing with a Krebs’ buffer, the vascular
preparations were contracted with phenylephrine (106
mol/L), and when the contractile response was stabilized
(steady-state phase, 12 to 15 minutes), vasorelaxing re-
sponses to cumulative increments in the concentration of
acetylcholine or NONOate were examined.14
Blood Glucose, Insulin Tolerance, and
Homeostasis Model Assessment Index
Plasma glucose was measured using glucometer (One-
Touch Ultra, Lifescan) by collecting 2 l blood through
nicking the end of the tail. To estimate insulin resistance,
we conducted insulin tolerance test and homeostasis
model assessment (HOMA) index analysis, as previously
described.15,16 Briefly, for the insulin tolerance test, ani-
mals were fasted for 3 hours. The mice were weighed and
1.5 units/kg body weight of diluted regular human insulin
1:1000 (0.1 inits/ml) was injected intraperitoneally. At 90
and 180 minutes, blood glucose was sampled. HOMA
index was calculated by the formula: fasting plasma in-
sulin  fasting plasma glucose/405.
Measurement of Cytokines/Chemokines
and Insulin
The Luminex multiplex assay (cat#: MCYTO-70K-PMX)
was used for simultaneous quantification of the following
mouse cytokines/chemokines in the plasma: interleukin
(IL)-1 and , IL-6, IL-9, IL-10, interferon (IFN), interfer-
one-gamma-inducible protein (IP-10), granulocyte-col-
ony stimulating factor (G-CSF), granulocyte-macro-
phage-colony stimulating factor (GM-CSF), tumor
necrosis factor (TNF), keratinocyte chemoattractant (KC),
monocyte chemoattractant protein (MCP-1), macrophage
inflammatory protein (MIP-1) and mRANTES. A mixture
of beads was incubated with standards or plasma sam-
ples, followed by the appropriate biotinylated antibody
and streptavidin-phycoerythrin reporter. Beads were an-
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alyzed using Luminex-100. Plasma insulin, amylin, gluca-
gon, and leptin concentration were simultaneously mea-
sured using the same technique (cat#: MENDO-75K-05).
Immunohistochemical and Immunofluorescence
Staining and Analysis
Tissue samples of kidney and pancreas were fixed in a
4% paraformaldehyde solution (Electron Microscopy Sci-
ences, Hatfield, PA) overnight at 4°C, followed by se-
quential incubation in 15% and 30% sucrose overnight at
4°C each. Embedding was performed in an optimal cut-
ting temperature compound (Tissue-Tek, Torrance, CA),
and embedded samples were stored at 80°C. Frozen
samples were cut into 10-m-thick sections (Cryomicro-
tom CM 1850, Leica Microsystems, Bannockburn, IL).
Nonspecific protein binding was blocked by 1-hour incu-
bation with PBS-bovine serum albumin (1%). The follow-
ing primary antibodies were used: anti-mouse insulin
(Santa Cruz Biotechnology, Santa Cruz, CA), CD31 (BD
Pharmingen, San Jose, CA), and CD68 (Serotec, Oxford,
UK). For CD-68 staining, horseradish peroxidase conju-
gated goat anti-rat IgG was used as the secondary anti-
body. Peroxidase activity was blocked by 15 minutes of
incubation with peroxidase block solution (1:10; DakoCy-
tomation, Glostrup, Denmark). To visualize the positive
immunoreaction, the peroxidase substrate 3,3-diamino-
benzidine chromogen was used. Hematoxylin solution
was used for counterstaining. Negative controls for all
immunolabeling procedures were accomplished by incu-
bation with 1% PBS-bovine serum albumin instead of the
primary antibody. For immunofluorescence staining, flu-
orescein isothiocyanate (FITC)-conjugated secondary
antibodies (Jackson ImmunoResearch Laboratories,
West Grove, PA) were used. Incubations with primary
antibodies were performed overnight at 4°C and incuba-
tions with secondary antibodies were performed for 1
hour at room temperature. Control samples were stained
with secondary antibodies only. To visualize the nuclei,
tissue sections were counterstained with 4,6-diamidino-
2-phenylindole (Molecular Probes). Sections were exam-
ined using a Nikon inverted fluorescence microscope
(Eclipse TE2000-U) equipped with a digital camera (Spot
model 4.2; Diagnostic Instruments, Sterling Heights, MI).
For histological examination of kidneys, paraffin-em-
bedded tissue samples were cut into 3-m-thick sections
and stained with H&E, periodic acid-Schiff, or Masson’s
trichrome (American MasterTeck, Lodi, CA). Slides were
examined and scored for abnormalities by two nephro-
pathologists. For detection of tubular necrosis, the scor-
ing range from 0 to 3 was used to define noticeable cell
damage in the form of hydropic change, cast formation,
necrosis or apoptosis in the tissue area. The scoring
criteria were defined as follows: score 0  no noticeable
cell damage; 1  noticeable cell damage in tissue area
10%; 2  noticeable cell damage in tissue area be-
tween 10 to 50%; 3  noticeable cell damage in tissue
area 50%. Additional 3 m-thick periodic acid-Schiff-
stained paraffin sections of kidneys were evaluated for
diabetic nephropathy from 4 different groups (n  3 in
each group): controls (m), diabetic (db), stem cell trans-
plantation from control mice (Tx M) and from db mice (Tx
db). Slides were examined by Olympus BX41 micro-
scope under 40 magnification. All glomeruli were
counted in a single cross section as well as the numbers
of lesioned microvessels, which were expressed as per
100 glomeruli. The normal mesangial area in the control
animals was assigned 0 score, with scores 1 if these
were twice the size of the control, 2 and 3 when
expanded to 3 and 4 times, respectively.
Fluorescence-Activated Cell Sorting
Bone marrow (BM)-derived mononuclear cells were ana-
lyzed for an array of markers, including FITC or phyco-
erythrin (PE) conjugated anti-mouse CD117 (c-kit),
CD150, sca-1, c-kit, CD34, CD31, CD44, CD45, flk,1,
and unconjucated anti-mouse vimentin, and nestin that
paired with corresponding fluorescent secondary anti-
body (Jackson ImmunoResearch Laboratories). All pri-
mary antibodies were produced by BD Biosciences
(Rockville, MD). Data were acquired using a FACScan
cytometer equipped with a 488-nm argon laser and a
620-nm red diode laser and analyzed using CellQuest
software (Becton Dickinson, San Jose, CA). The setup of
FACScan was performed using unstained and single an-
tibody-stained cells.
BM-Derived MSC and Endothelial Progenitor
Cell Isolation
To isolate MSCs from the bone marrow of db/db and
db/m mice, the fresh BMDC preparations were re-sus-
pended in complete MSC culture medium (StemCell
Technologies Inc, Canada) and seeded into 6-well
plates. The cells were than kept 3 days at 37°C in a CO2
incubator, fresh medium was changed, and the adherent
layer was re-fed at 7 days. For analysis of apoptosis cells
from 1 to 2 passages were used. To isolate endothelial
progenitor cells (EPCs), BMDC were re-suspended in
mouse EPC medium (Celprogen, San Pedro, CA) supple-
mented with 10% fetal bovine serum. Seven days after
initiation of cultures on 4-well chamber slides (Nalge
Nunc International) coated with Vitronectin (10 g/ml),
EPCs were assayed by costaining with acetylated LDL
(acLDL)-Dil (Biomedical Technologies) for 3 hours at
37°C and FITC-conjugated Ulex europeaus Lectin
(Sigma) for 30 minutes at 37°C, both characteristically
staining cells of endothelial lineage.17 Double-positive
cells were counted as EPC in eight randomly selected
fields of each slide. The proportion of apoptotic cells
under basal and oxidative stress conditions, as detailed
in Results, was examined using annexin V (BD pharmin-
gen) and activated caspases detection using FITC-VAD-
FMK (Calbiochem, La Jolla, CA).
Statistical Analysis
Results were summarized from three independent BM
transfusion experiment and the numbers of mice for each
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study group were totaled: db/m n  24, db/db control
mice n  20, dbCM n  4, dbEbs-in vivo n  5, dbTxm
mice n  10, dbTxdb mice n  9, TxdbCM n  4,
TxdbEbs-in vivo n  5, and TxdbEbs-ex vivo n  5. The
results were expressed as means  SD The means of
two populations were compared by Student’s t-test. For
multiple comparisons analysis of variance was used. Differ-
ences were considered significant at P  0.05.
Results
Defective Vasorelaxation in db/db Mice is
Dramatically Improved by Transfusion of
Syngeneic BMDCs
We have previously demonstrated that conspicuous de-
fects in endothelium-dependent vasorelaxation of aortic
rings in db/db mice could be detected as early as 9 to 10
weeks of age, ie, just 2 weeks after establishment of a
persistent hyperglycemia,14 in association with the in-
creased numbers of prematurely senescent endothelial
cells. Therefore, we pursued these studies of the macro-
vascular dysfunction in db/db mice recipients of BMDC
transplants using acetylcholine-induced vasorelaxation
assay. Aortic rings obtained from db/db mice showed a
profound impairment of relaxation in response to the
application of acetylcholine (Figure 1A). Maximal con-
centration of acetylcholine (100 mol/L) elicited only a
29% relaxation of aortic rings compared with db/m mice.
In contrast, db/db mouse-recipients of BMDC from db/db
donors (dbTxdb group) showed a mild-to-moderate im-
provement of aortic relaxation (maximal relaxation of
56%), whereas the db/dbmice receiving BMDC from their
db/m littermates (dbTxm group) exhibited a dramatic
improvement of aortic vasorelaxation with the maximal
values achieving 81% of control db/m mice. Notably, all
vessels responded to nitric oxide (NO) donor NONOate
with equal relaxation (Figure 1B), thus indicating that the
impaired responses to acetylcholine were due to defec-
tive endothelium-dependent relaxation.
BM Adoptive Transfer Improves Fasting
Glucose Level and Insulin Sensitivity
Monitoring blood glucose levels in db/db recipients of
BMDC infusions (10 days after each infusion and 20 days
after the last infusion) indicated a significant improvement of
fasting blood glucose level in recipients of BMDC from db/m
donors (dbTxm group) (Figure 2A). In mice that received
BMDC from db/db donors (dbTxdb group), the improve-
ment in fasting blood glucose level was transient and oc-
curred only after the first transfusion, when the BMDC donor
db/db mice were 8 weeks old (this is the age when hyper-
glycemia commences in db/db mice). Hyperglycemia re-
sumed after the subsequent transfusions and was indistin-
guishable from non-treated db/db mice of equivalent age.
Treatment of db/db mice with BMDC of either origin did
not affect their body weight and all animals remained
equally obese (Figure 2B). The results of the insulin toler-
ance test performed 20 days after the last BM transfusion
showed that the sensitivity of mice to the injected insulin in
the dbTxm group was improved compared with db/db con-
trol and dbTxdb group, although hypoglycemic responses
remained equally delayed (Figure 2C), suggesting that the
observed improvement of fasting blood glucose level in db/db
recipients of BMDC from db/m donor mice was secondary to
improved insulin sensitivity rather than reduced obesity.
To further address the possibility that BM adoptive
transfer can improve insulin sensitivity in the recipient
diabetic mice, we measured their fasting plasma insulin,
amylin, and glucagon level. Compared with db/db mice
that exhibited elevated plasma insulin and amylin level,
mice in the dbTxm group showed normalization of hyper-
insulinemia and hyperamylinemia, whereas dbTxdb mice
showed no improvement in insulin and only a partial
improvement in amylin level (Figure 3, A and B). In ac-
cord with these results, the calculated glucose/insulin
ratio and HOMA index showed significant improvement in
the dbTxm group compared with db/db control and
dbTxdb mice (Figure 3, C and D). Plasma glucagon
measurements showed no significant differences be-
tween all of the experimental groups (Figure 3E). In ag-
gregate, having excluded the contribution of other factors
to the improved insulin sensitivity, the most plausible expla-
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Figure 1. Acetylcholine-induced vasorelaxation of aortic rings. A: Cumula-
tive dose-response curves of acetylcholine-induced vasorelaxation in phen-
ylephrine-preconstricted aortic rings. Significant improvement in acetylcho-
line-induced vasorelaxation was documented for db/db mice after
transfusion of BMDC, especially in db/db recipients of BMDC isolated from
db/m counterparts. B: Cumulative dose-response curves of NONOate-in-
duced vasorelaxation in denuded phenylephrine-preconstricted aortic rings
showed comparable responsiveness among all different groups. *P  0.01 vs
db/m, dbTxm; #P  0.05 vs dbTxdb.
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nation is found in the BMDC-induced alleviation of endothe-
lial dysfunction and improvement of microcirculation.
Cytokine Profile of db/db Mice after BM
Adoptive Transfer Suggest an Inflammation
Independent Mechanism for the Observed
Benefits
Another possible explanation for the observed improved
insulin sensitivity was related to the modulation of pro-
inflammatory mediators.18 To explore this possibility we
measured the plasma concentration of 14 pro- and anti-
inflammatory cyto- and chemokines (IL-1 and , IL-6,
IL-9, IL-10, IFN, IP-10, G-CSF, GM-CSF, TNF, KC,
MCP-1, MIP-1, and mRANTES) following BM transfu-
sion. The results showed elevated levels of IL-1 and
G-CSF after BM transfusion regardless of the donors,
elevated levels of IP-10 in dbTxm and elevated IL-10
levels in recipients of db/db BMDC (supplemental Figure
1, see http://ajp.amjpathol.org).
In addition, we analyzed the extent of macrophage/
mononuclear infiltration of the pancreatic and kidney
parenchyma (supplemental Figure 2A, see http://ajp.
amjpathol.org). Immunohistochemical staining showed
that the CD68-positive cells were rare and scattered
evenly in the pancreas and kidney sections with no dif-
ferences detectable among the studied groups (supple-
mental Figure 2B–C, see http://ajp.amjpathol.org).
The above analyses indicated the existence of low-
grade pro-inflammatory conditions following the infusion
of BMDC. These data ruled out the possibility that the
improved insulin sensitivity following BM transfusion
was due to the improved profile of pro-inflammatory
cytokines.
No Evidence of Trans-Differentiation of the
Engrafted Donor BMDC to Insulin-Producing
Cells in the Pancreas
To examine the possibility of trans-differentiation of en-
grafted donor BMDC to insulin-producing cells and eval-
uate its contribution to the observed benefits following
BM transfusion, we studied frozen sections of the pan-
creas. Fluorescent microscopy confirmed the presence
of CM-Dil positive donor BMDC in the recipient’s pan-
creas (supplemental Figure 2D, see http://ajp.amjpathol.
org). These scattered cell tracker-labeled cells were rare
and showed no difference in frequency between dbTxm
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Figure 2. Fasting blood glucose level and insulin tolerance test. A: Im-
provement of fasting glucose level was documented in the dbTxm group
following each infusion of the BMDC, compared with untreated db/db
mice. In the dbTxdb group, improvement of fasting glucose level was
documented only after the first infusion. *#P  0.05 vs db/db. B: Body
weight measurement indicated that the diabetic mice were all obese
compared with db/m, but showed no difference between db/db, dbTxm,
and dbTxdb groups. C: Insulin tolerance index in BM transplanted group
showed significant improvement in insulin sensitivity over db/db mice,
especially in the dbTxm group. *P  0.01 compared with db/db at 90 and
180 minutes, P  0.05 compared with dbTxdb group; #P  0.05 compared
with db/db at 90 and 180 minutes (n  6 for db/m, dbTxm, and dbTxdb
groups, n  5 for db/db).
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Figure 3. Analysis of hormones regulating glucose level. A, B, and E: com-
parison of plasma insulin, amylin, and glucagon level among experimental
groups. C and D: analysis of glucose/insulin ratio and HOMA index showed
improved insulin sensitivity in dbTxm group compared with db/db control.
Results are based on the study of n  6 for db/m, dbTxm, and dbTxdb
groups; n  5 for db/db.
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and dbTxdb group. Examination of the pancreas co-
stained with anti-mouse insulin antibody failed to show
insulin-positive staining of engrafted donor BMDC (data
not show). Immunohistochemical staining of insulin
showed comparable density and normal morphology of
the islets among db/m, db/db, and BMDC-treated dia-
betic mice (data not show). Quantification of the islets
showed equal levels among different experimental
groups (supplemental Figure 2E, see http://ajp.amjpathol.
org). Our results suggested that a direct trans-differenti-
ation to insulin-producing cell was not evident in the
pancreas, and BMDC transfusion did not influence pan-
creatic islands structure and density.
Renal Function Improves in a Subgroup of db/
db Mice after Treatment with BMDC from db/m
Donors; Risk of Tubular Necrosis in Bone
Marrow Transplantation
Effects of BMDC adoptive transfer on renal function in
db/db mice were examined. The recipients of BMDC from
db/m donors exhibited improved renal function (Figure 4,
A and B) judging from urinary protein/creatinine ratio and
plasma creatinine level. Glomeruli showed mild to mod-
erate hypertrophy in all db/db animals compared with
controls and in addition displayed mesangial expansion
(range, 2 to 2.5; average 2.3) and arteriolar hyalinosis
(range, 8% to 18%; average 9%; supplemental Figure 3,
see http://ajp.amjpathol.org). An occasional lesion of focal
and segmental glomerulosclerosis, containing extracel-
lular lipid droplets, was also evident (1/3 animals) in
db/db mice. Kidneys from dbTxm group showed mild
decrease in mesangial expansion (range 1.5 to 2.0; av-
erage 1.66) and in areteriolar hyalinosis (range, 2% to
4%; average 3.3%). No lesions of focal and segmental
glomerulosclerosis were present in any of these sections
obtained from dbTxm mice. The decline in mesangial
expansion (range, 2 to 2.5; average 2.17) and in arete-
riolar hyalinosis (range, 2% to 7%; average 4.66%) were
less impressive in the dbTxdb animals. An occasional
lesion of focal and segmental glomerulosclerosis was
evident in one of the three animals as well.
Of note, these changes were not universal and analy-
sis showed that there was a subgroup, which was ana-
lyzed separately (40%), that showed the deterioration of
proteinuria and plasma creatinine level after BM transfu-
sion from either donor group. (Figure 4, C and D). Con-
sistent with these findings, histological examination of
kidney sections revealed elevated pathological score of
tubular necrosis in this subgroup along with an increased
glomerular volume (Figure 4E). These findings are not
inconsistent with multiple clinical observations that
pointed out the risk of acute kidney injury in 53% to 92%
after BM transplantation.19–21 Despite the syngeneic na-
ture of transplanted cells, it is not excluded that the
procedure itself carries a risk of acute tubular necrosis,
probably due to the formation of cellular clamps in the
injectate. The performed “grouping” presented an at-
tempt to objectively analyze beneficial and adverse ac-
tions of transplantation of BMDC in the kidney.
Profiling of Cell Markers for BMDC of the Donor
db/db and db/m Mice
Some of the detected beneficial effects of the adoptive
transfer of BMDC in db/db mice could be secondary to
the infusion of the progenitor/stem cell population present
in the isolated donor BMDC. Differences in composition
could hence affect their beneficial outcomes, which may
also reflect the existed changes in the BM progenitor/
stem cell population under normal versus disease condi-
tion. We used an array of cell surface markers to profile
the freshly isolated BMDC (pooled from at least four
animals for each group) using FACS analysis (Figure 5),
including sca-1, c-kit, CD34, flk-1, CD44, vimentin, and
nestin. The results from two independent experiments
showed no substantial differences in the expression of
detected markers between db/db and db/mmice, except
for some noticeable discrepancy in sca-1 and nestin.
BMDC used for transfusion were represented mostly by
mesenchymal and hematopoietic stem cells nearly equally
represented numerically in db/m and db/db bone marrow,
but proportional differences in some markers do exist.
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Figure 4. Analysis of renal function following BM transfusion. Urine pro-
tein/creatinine ratio (A) and serum creatinine concentration (B) measure-
ments in the recipients of BMDC from db/m donor mice showed improve-
ment in these parameters. In approximately 40% of animals, however,
analysis of the urine protein/creatinine ratio (C) and serum creatinine level
(D) showed deterioration in recipients of db/m or db/db BMDC infusion.
Results of the analysis of pathology scores in this subgroup (E) showed
increased level of tubular necrosis following BMDC infusion. The number of
animals studied in (A, B, and C)  db/db n  5, dbTxm n  6, dbTxdb n 
6; and, (D and E)  db/db n  3, dbTxm n  4, dbTxdb n  4.
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Functional Analysis of BMDC and their
Progenitor/Stem Cell Population in the Donor
db/db and db/m Mice
Although the surface markers of cells in the transfused
BMDC of either type of the donor, db/db or db/m, ap-
peared to be little unchanged, the end-effects of their
transfusion were much different, as shown in Figures 1
and 2. To evaluate the possibility that the infused BMDC
differed qualitatively, we analyzed the viability of BMDC
and their progenitor/stem cell population by study the
markers of apoptosis under basal and stressed condi-
tions. FACS analysis of Annexin V staining showed com-
parable percentages of positive cell in freshly isolated
db/db and db/m mice BMDC (Figure 6A). This result was
confirmed with Hoechst staining. We then tested the re-
sistance of the isolated BMDC to challenge with H2O2 (50
mol/L) or glycated collagen I (GC, 50 g/ml, a mimic of
diabetic microenvironment; Figure 6B). Though the fre-
quency of apoptosis was comparable between db/db
and db/m groups under the basal conditions and after
exposure to native collagen (NC, 50 g/ml), the rate of
apoptosis was significantly elevated in the db/dbmice on
exposure to H2O2 or GC stress.
In addition to the freshly isolated BMDC, we also char-
acterized stress resistance of MSCs isolated from db/db
and db/m mice (Figure 6, C and D). The results summa-
rized from both the short overnight stress (C) and pro-
longed 3 days stress (D) indicated a significantly higher
apoptotic population among MSC isolated from db/dbmice
compared with that of db/m counterparts, even under the
basal culture condition (control and NC). These differences
in the rate of apoptosis were further markedly increased in
both groups of mice on H2O2 and GC challenge, but were
significantly higher in the db/db group mice.
Ex Vivo and in Vivo Ebselen Treatment
Corrects Stem Cell Competence
We have previously demonstrated beneficial vascular ef-
fects of a selenoorganic peroxynitrite scavenger and an-
tioxidant, Ebselen, in Zucker diabetic rats14 and, there-
fore, tested its potential to improve the resistance to
stress of BMDC and their functional competence. The
addition of Ebselen (Ebs) to BMDC culture medium
prevented apoptosis under basal and H2O2 stress con-
ditions, as detected by the activated caspases using
FITC-VAD-FMK probe (Figure 6E). Compared with vehi-
cle-treated control, in vivo chronic administration of Ebs
by gavage decreased the rate of apoptosis in BMDC
from db/db mice.
In view of the differences encountered during ScaI and
Flk1 profiling (Figure 5), we further tested the possibility
that the EPCs in BMDC population may vary between
db/db and db/m mice. FACS analysis showed that db/db
BMDC contained less ScaI/Flk1 cells (Figure 7C).
EPCs cultured from db/db mice also showed decreased
number and elevated apoptosis rate (Figure 7, A and B).
In vivo treatment of db/db mice with Ebs restored viability
and increased the EPC population. The recipients of the
BMDC obtained from in vivo Ebs-treated db/db mice
showed an increased BM EPC population and decreased
apoptotic rate in EPCs (Figure 7, D–F). BMDC from db/db
mice treated with Ebs ex vivo (overnight) also elicited
improved endothelium-dependent relaxation after trans-
Figure 5. FACS analysis of cell markers in BMDC. Freshly isolated BMDC
were analyzed for their composition using a panel of markers related to BM
stem/progenitor cells. No substantial differences were observed in the ex-
pression of detected markers between db/db and db/m mice, except for
some noticeable distinctions in Sca-1 and nestin. The results for db/db mice
are shown in black, db/mmice in gray. Ranges are given for two independent
experiments.
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(Ebs) to BMDC culture medium prevented apoptosis under basal and H2O2
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staining. *†P  0.05 compared with db/m within each treatment; #‡P  0.05
compared with each corresponding control; **P  0.05 compared with H2O2
treatment; ##P  0.05 compared with dbCM. The number of animals: n  4
for db/m, db/db, and dbCM groups; n  5 for dbEbs-in vivo group.
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plantation to db/db recipient mice, which was accompa-
nied by increased EPC number within their BMDC pop-
ulation. In parallel, improvement of the endothelium-
dependent relaxation in response to acetylcholine
(Figure 8A; compare with Figure 1A) ensued. Specifi-
cally, in vivo and ex vivo therapy with Ebs resulted in
maximal relaxation to acetylcholine reaching 55% and
61% of control db/m mice, respectively, compared with
38% of maximal relaxation in vehicle-treated group.
To evaluate the possible engraftment to the microvas-
culature, we stained the kidney sections with CD31
monoclonal antibody (Figure 8B). Fluorescence micros-
copy followed by deconvolution analysis indicated that
some of the engrafted CellTracker-labeled infused BMDC
co-expressed CD31 and could be localized to the renal
microvasculature. While this double-staining was a rarity
in recipients of BMDC from db/db mice, such double-
stained cells were readily detectable in the recipients of
BMDC from db/m mice.
The urine albumin/creatinine ratio of recipients of
BMDC obtained from Ebs-treated donor db/db mice also
showed improvement compared with recipients of BMDC
obtained from vehicle-treated mice (Figure 8C). In con-
clusion, Ebselen treatment both in vivo and ex vivo re-
stored competence to BMDC, improved EPC resistance
to oxidative stress and was associated with improved
vascular and renal function. These findings suggest that
targeting the competence of endogenous BMDC may
represent an alternative strategy in managing complica-
tions of type II diabetes and metabolic syndrome.
Discussion
Strategy of bone marrow transplantation has recently
been adapted as an important procedure to pinpoint
novel therapeutic approaches and to reveal new patho-
genic mechanisms for many insidious human diseases.
Type I diabetes models have been used in several recent
studies to evaluate the existence of adult progenitor/stem
cells in the BM not only for merely mechanistic insights
but also the development of new curative strategies.8
Implantation of autologous BMDC in the ischemic hind-
limb of diabetic rats enhanced the angiogenesis and
improved vascularization that contributed to faster recov-
ery.5 Transplantation of syngeneic BMDC after acute in-
jury also promoted -cell regeneration in pancreas.10
However, the models of type II diabetes have been
scarcely explored with regard to the effects of BMDC
transplantation.7
In the present study using db/db mice, a well recog-
nized animal model of metabolic syndrome and type II
diabetes, we made two important observations using
BMDC adoptive transfer. Firstly, infusion of BMDC ob-
tained from the db/m littermates dramatically improved
the macrovascular function (acetylcholine-induced relax-
ation of aortic rings) and insulin sensitivity in the recipient
db/db mice. Secondly, these observed beneficial effects
of treatment were nearly absent when the BMDC ob-
tained from diabetic donor mice were used. The mecha-
nism(s) for these observed beneficial metabolic out-
comes of BMDC infusion were not apparent. After an
extensive search, we were able to exclude several po-
tential candidates, such as changes in the degree of
obesity (body weight remained stable), improvement of
pro-inflammatory cytokines profile (in fact there was ele-
vation of G-CSF and IL-1, although anti-inflammatory
IL-10 levels also increased, especially in the dbTxdb
group), and disparate engrafting ratio of the transfused
BMDCs (comparable number of engrafted CM-DiI posi-
tive cell were found). These data, in conjunction with
dramatic improvement of vascular function in dbTxm
mice argue in favor of a conclusion that circulatory mech-
anisms underlie the observed correction of insulin sensi-
tivity. The possibility of changes in adiponectin levels
being responsible for metabolic benefits in dbTxm group
remains to be evaluated. It is also not clear whether the
improved glycemic control in dbTxm group is responsi-
ble for amelioration of vascular and renal complications in
db/dbmice or BMDC transplantation has separate effects
on metabolic, vascular and renal manifestations.
The differences in the study outcome using BMDCs
that originated from normal or diabetic animal are strik-
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Figure 7. Analysis of BM-derived EPC. FACS
analysis and direct cell culture of BMDC showed
decreased EPC numbers (A, B) and increased
EPC apoptosis (C) in db/db mice. In vivo treat-
ment of db/db mice with Ebs increased their BM
EPC population and normalized their apoptosis
rate. Compared with the recipient of BMDC of
vehicle treatment, the db/db mice transferred
with BMDC of Ebs treated db/db donor mice (in
vivo and/or ex vivo) showed increased BM EPC
number (D, E) and decreased apoptosis (F).
*P  0.05 compared with db/m or TxCM; #P 
0.05 compared with dbCM. The number of ani-
mals: n  4 for db/m, db/db, dbCM, and TxCM
groups; n  5 for dbEbs-in vivo, TxdbEbs-in
vivo, and TxdbEbs-ex vivo groups.
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ing. The possibility that it may reflect the alterations in cell
composition and competence, both in general and pro-
genitor/stem cell population, as well as alternations in cell
functionality appear to deserve credence. The existence
of dysfunctional EPCs originating from BM has been
documented in atherosclerosis,6,22 essential hyperten-
sion,23,24 preeclampsia,25 hyperglycemia,26 smoking24,27
and type I and type II diabetes patients.28–30 It has recently
been shown that diabetic state promotes aging of cardiac
stem cells, a tissue resident stem cell population, and con-
tribute to the heart failure.31
We explored this hypothesis further in our BMDC trans-
plant setting. Referring to the initial finding that the ScaI-
or Flk1-positive cell were decreased in BMDC of db/db
mice, we further analyzed the cell population double-
positive for ScaI and Flk1, the proposed EPC population.
A decreased percentage of BM ScaI/Flk1 cells was
documented in db/db mice by FACS analysis. This find-
ing was supported by experiments on cultured EPC and
is consistent with the results from others.28–30,32,33 Next,
we qualitatively tested their viability and resistance to
oxidative stress in cell culture. An increase in apoptosis
under basal culture conditions was detectable in BMDC
of db/db origin, as well as in the MSC and EPC. Chal-
lenging BMDC and MSC with oxidative stress (H2O2) or a
glycated long-lived protein (GC) disclosed alterations in
db/db mice. Proportion of apoptotic cells after H2O2 or
GC treatment was significantly higher in the BMDC and
MSC prepared from diabetic mice.
Having demonstrated functional incompetence of
BMDC obtained from db/db mice, we attempted to cor-
rect it using the selenoorganic antioxidant and peroxyni-
trite scavenger Ebs. Ex vivo treatment of cultured BMDC
with Ebselen resulted in a significant improvement of their
resistance to oxidant stress and reduced rate of apopto-
sis. In vivo therapy of db/db mice with Ebs also reduced
the rate of apoptosis in BMDC and EPC in culture and
normalized the number of EPC. Furthermore, adoptive
transfer of the BMDC from db/db mice treated with Ebs in
vivo or ex vivo produced striking reduction of vasculopa-
thy and improvement of renal function in recipient db/db
mice. These functional improvements in recipient db/db
mice were associated with much improved resistance to
apoptosis and elevated EPC numbers in their BM. This
finding may explain at least in part the compromised
state of BMDC isolated from db/db mice. However, these
data also added another interesting layer of complicity to
the mechanisms for the benefits following adaptive trans-
fer. In contrast to the improved vasculopathy and renal
dysfunction, the beneficial effect on fasting glucose level
and insulin sensitivity were absent in the recipients of
BMDC transfer from db/db mice treated with Ebs (data
not shown). This disparity suggests that the variety of
beneficial effects in db/db recipients of db/m BMDC
transfer may be well mediated through multiple mech-
anisms, which are all compromised in db/db mice.
Some of these compromised mechanisms in db/db
mice are improved with the use of antioxidant therapy,
but some are not.
In contrast to renal functional improvement in the ma-
jority of recipient animals in the present study, the dete-
rioration of renal dysfunction in a subgroup stands apart.
Our own data obtained in mice with acute kidney injury,34
as well as previous findings by Prockop’s group35 in
streptozotocin-diabetic mice all showed beneficial effect
of infused MSC on renal function. In another study re-
ported by Cook’s group, transplantation of wild-type
BMDC improved renal function in Col43/ mice
through, in part, a mechanism involving regeneration of
padocytes without the gene defect.36 These distinct out-
comes may be due to severity of hyperlipidemia in db/db
mice or to circulating cells as referred to in the previous
work by Striker’s group.37 Secondly, these findings may
be linked to the BMDC transplantation per se. The de-
cades of experience with bone marrow transplantation
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Figure 8. Analysis of Acetylcholine-induced vasorelaxation of aortic ring,
CD31 staining of kidney section, and urine albumin/creatinine level. A:
Cumulative dose-response curves of acetylcholine-induced vasorelaxation in
phenylephrine-preconstricted aortic rings. Compared with BMDC of db/db
mice (Txdb group), better improvement in acetylcholine-induced vasorelax-
ation was documented for recipient mice after transfusion of BMDC of donor
db/db mice that treated with Ebs both in vivo and ex vivo (Txdb-Ebs in vivo
and Txdb-Ebs ex vivo). Cumulative dose-response curves of NONOate-
induced vasorelaxation in denuded phenylephrine-preconstricted aortic
rings showed comparable responsiveness among all different groups (not
show). *P 0.05 compared with db/db in all tested acetylcholine level above
0.005 umol/L for db/m and 5 umol/L for Txdb; **P  0.05 compared with
db/db and Txdb in all tested acetylcholine level above 0.005 umol/L. The
number of animals: n  8 for db/m, db/db, and Txdb groups; n  6 for
TxdbEbs-in vivo and TxdbEbs-ex vivo groups. B: Ultrathin deconvoluted
images (0.625 m) showed that some of the engrafted CellTracker-labeled
cells (infused BMDC) co-expressed CD31 (an endothelial marker) and could
be localized to the renal microvasculature. C: The recipient of BMDC in in
vivo Ebs-treated mice showed improved urine albumin/creatinine levels
indicating the improvement of renal function. #P  0.05 as compared with
TxCM.
Stem Cell Incompetence in Diabetic Mice 709
AJP February 2009, Vol. 174, No. 2
buttress these findings. The incidence of renal dysfunc-
tion of various degrees ranges from 53% to 92% with 24%
of patients requiring dialysis.19–21 Development of pro-
teinuria was found to be near-universal after bone marrow
transplantation.38 In our experimental setting, despite the
fact that a syngeneic transplantation was performed, the
possibility of microembolism due to cell clamping, both in
BMDC from db/db and db/m donors, cannot be ruled out
and was presumably the cause of the observed tubular
necrosis.
In conclusion, infusion of BMDC obtained from db/m
donors to db/db recipient mice benefited macrovascular
function, insulin sensitivity, and, in majority of cases, renal
function. The BMDC obtained from db/db mice were func-
tionally incompetent partly secondary to their decreased
viability under increased oxidative stress challenge. Our
work emphasizes benefits and risks of cell therapy, and
reduced competence of BMDC in db/db mice, and sug-
gests that antioxidant targeting of BMDC, both in situ or ex
vivo, may represent an alternative strategy in managing
complications of type II diabetes and metabolic syndrome.
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